FDA Partial Hold on Cancer Drug Adds to Molecular Templates’ Growing List of Woes
The FDA has asked for more information about cardiac complications reported last year in a Phase 1 study for the Molecular Templates cancer drug, MT-0169. The partial clinical hold comes as the biotech works through a corporate restructuring as well as a second Nasdaq de-listing notice.